AQST - CIK 0001398733
Aquestive Therapeutics, Inc. (AQST) reported net income of -$83.78M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$83.78M | -89.8% |
| FY 2024 | -$44.14M | -460.8% |
| FY 2023 | -$7.87M | +85.5% |
| FY 2022 | -$54.41M | +22.9% |
| FY 2021 | -$70.54M | -26.5% |
| FY 2020 | -$55.78M | +15.8% |
| FY 2019 | -$66.25M | -7.9% |
| FY 2018 | -$61.38M | -586.3% |
| FY 2017 |
Aquestive Therapeutics, Inc. (AQST) reported net income of -$83.78M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Aquestive Therapeutics, Inc.'s net income declined from -$8.94M to -$83.78M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$8.94M |
| - |